We recently published a list of 7 Best Nanotech Penny Stocks to Invest In. In this article, we are going to take a look at where Clene Inc. (NASDAQ:CLNN) stands against other best nanotech penny stocks to invest in.
Nanotech involves working with tiny particles which are about the size of molecules. This field is being used to improve products in many different industries, like electronics, medicine, and energy. By manipulating matter at this tiny scale, materials and devices with special properties can be made. The global nanotech market was valued at $3.69 billion in 2022 and is projected to grow at a 33.1% CAGR from 2023 to 2030, as reported by Grand View Research. This is driven by the increased use in medical diagnostics and imaging, technological advancements, substantial R&D funding, and the creation of advanced materials for healthcare, electronics, aerospace, textiles, transportation, manufacturing, and agriculture.
In 2022, nanodevices dominated the nanotech market, accounting for over 58% of global revenue. This was due to their potential in healthcare (targeted drug delivery, imaging, diagnostics, regenerative medicine) and electronics (smaller transistors, memory devices, sensors). Nanosensors, which are crucial for nanoscale detection and measurement across many industries, are projected to grow. Healthcare and pharmaceuticals led applications in 2022, with over 26% market share. This was driven by the increased use of nanotech in areas like surgical nano-robots, nano-diagnostics, and targeted drug delivery, as well as rising chronic disease prevalence and surgical procedures. The automobile segment is also expected to grow due to nanotech’s improvements in materials, energy efficiency, safety, and functionality.
While the nanotech industry as a whole holds promise, it is still in its early innings and many companies are in the small-cap territory.
Methodology
We first sifted through ETFs, online rankings, and internet lists to compile a list of the top nanotech stocks under $5. We then selected the 7 stocks that were the most popular among elite hedge funds and that analysts were bullish on. The stocks are ranked in ascending order of the number of hedge funds that have stakes in them, as of Q3 2024. The hedge fund data was sourced from Insider Monkey’s database which tracks the moves of over 900 elite money managers.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
A medical patient receiving treatment at a clinical trial center.
Clene Inc. (NASDAQ:CLNN)
Number of Hedge Fund Holders: 2
Share Price as of February 11: $4.52
Clene Inc. (NASDAQ:CLNN) is a clinical-stage pharmaceutical company that develops novel clean-surfaced nanotech (CSN) therapeutics. Its lead candidate, CNM-Au8 is a gold nanoparticle suspension. It’s being investigated for neurodegenerative diseases like ALS and Parkinson’s, as well as optic neuropathy. It’s also developing silver and zinc-based nanoparticle treatments for infectious diseases and wound healing.
It has a lot of focus on CNM-Au8, which is a nanomedicine designed to treat neurodegenerative diseases by improving mitochondrial health and protecting neuronal function. It’s an oral suspension of gold nanocrystals. The company’s immediate priority is securing regulatory approval for CNM-Au8 in amyotrophic lateral sclerosis (ALS). To support its approval, Clene Inc. (NASDAQ:CLNN) is gathering additional data, specifically focusing on Neurofilament Light (NfL) biomarker data. This data is being collected from ongoing Expanded Access Protocols (EAPs) and the HEALEY ALS Platform Trial. The company plans to submit an NDA for ALS in mid-2025.
The company reported $14.6 million in cash, cash equivalents, and marketable securities as of Q3 2024. Following this reporting period, Canaccord analyst Sumant Kulkarni reduced the company’s price target from $86 to $83 in November, while maintaining a Buy rating. Canaccord cited the lack of information about the Q3 meeting’s outcome as a factor to watch, as it could impact the stock price in the near term.
Overall, CLNN ranks 4th on our list of best nanotech penny stocks to invest in. While we acknowledge the growth potential of CLNN, our conviction lies in the belief that AI stocks hold great promise for delivering high returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than CLNN but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap
Disclosure: None. This article is originally published at Insider Monkey.